Yang et al. reported that PFKFB3 was expressed at higher levels in the proliferative phase of IH than in the regressive phase, and its inhibition significantly reduced tumor growth and angiogenesis in IH, highlighting PFKFB3 as a potential new therapeutic target for IH (Yang et al., 2023). This evidence concerns the gene PFKFB3 and neoplasm.